Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib

Autor Onn, A, Tsuboi, M, Thatcher, N
Vydáno 2004

L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients

Autor Portal, D, Hofstetter, L, Eshed, I, Dan-Lantsman, C, Sella, T, Urban, D, Onn, A, Bar, J, Segal, G
Vydáno v Cancer Manag Res (2019)

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

Autor Rodon, J., Soria, J. C., Berger, R., Batist, G., Tsimberidou, A., Bresson, C., Lee, J. J., Rubin, E., Onn, A., Schilsky, R. L., Miller, W. H., Eggermont, A. M., Mendelsohn, J., Lazar, V., Kurzrock, R.
Vydáno v Ann Oncol (2015)